Next Generation Cell Therapy Will Expand Global Patient Access
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 18 Analysts
Published
01 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$76.55
53.5% undervalued intrinsic discount15 Aug
US$35.56
1Y
-38.2%7D
-5.2%